Four 2026 Provisional Applications (Patent Pending), Held Separate From Three Issued U.S. Patents in Proteomics
From drug target identification to dynamical-state assessment methods: a journey of discovery that bridges biology, physics, and information theory through first-principles mathematical approaches.
Filed across cardiac diagnostics, molecular phenotyping, and early-warning detection, held separate from the three issued proteomics patents below.
A device-invariant, interpretable ECG review layer that assesses a patient's cardiac dynamical state from as little as a single lead, built to abstain and flag for human review rather than force a low-confidence guess. Filed provisional, research-stage.
An objective, blood-based molecular stratification signal for a condition still diagnosed by symptom criteria and exclusion, built on real cohort data. Filed provisional, research-stage.
A white-box host-response signature from a single blood draw plus an interpretable trajectory-review layer that tracks whether a patient is improving or worsening, offered alongside clinical judgment, not as a replacement. Filed provisional, research-stage.
An interpretable, physically-grounded early-warning monitor that tells you honestly when it can and cannot see trouble coming, positioned as an auditable governance and fallback layer for high-stakes decisions. Filed provisional, research-stage.
A device-invariant, interpretable ECG review layer assesses a patient's cardiac dynamical state from as little as a single lead. The method is training-free, built from first-principles signal geometry rather than a model fit to a labeled dataset, and is designed to abstain and flag for human review when its own confidence is below threshold, rather than force a guess.
An objective, blood-based molecular stratification signal targets a condition still diagnosed today by symptom criteria and exclusion. The method is built on real cohort data, and the work is honest about which sub-signals hold up under scrutiny and which do not.
A white-box host-response signature from a single blood draw, paired with an interpretable trajectory-review layer, tracks whether a patient is improving or worsening. The tool is offered alongside clinical judgment, never as a replacement for it.
An interpretable, physically-grounded early-warning monitor tells you honestly when it can and cannot see trouble coming. It corroborates classical critical-slowing-down theory and is positioned as an auditable governance and fallback layer for high-stakes decisions currently made by an opaque model alone, not as a claimed improvement over deep-learning baselines.
Co-inventor on foundational proteomics patents
Novel approaches to identifying and validating therapeutic targets
Computational biology methods for molecular structure analysis
LIMS architecture for research data management
Therapeutic approaches for stroke treatment
Whether you're exploring licensing opportunities, research partnerships, or technology transfer, let's discuss how this universal framework might apply to your domain.